Plus Therapeutics reported three clinical updates for its targeted radiotherapeutic REYOBIQ (rhenium-186 obisbemeda) at the WFNOS/SNO annual meeting, underscoring momentum across recurrent glioblastoma and leptomeningeal metastases. Early multi-dose data in the Phase 1/2 LM study showed initial patients treated without dose-limiting toxicity, while the Phase 1 portion of the GBM program linked higher absorbed tumor dose to longer survival and supported a 22.3 mCi recommended Phase 2 dose. An imaging analysis across GBM patients indicated that MRI combined with SPECT biomarkers correlates with coverage, progression-free survival, and overall survival, suggesting a path to patient-specific planning. Phase 2 enrollment in GBM has reached 24 of a planned 34 patients.
The strategic thread is precision. REYOBIQ is administered locally to CNS tumors, with SPECT/CT confirming high intratumoral retention and minimal systemic exposure. In a space where systemic drugs struggle to cross the blood–brain barrier and demonstrate meaningful benefit, Plus is advancing a dosimetry-led, image-guided approach that could redefine how radiopharmaceuticals compete in neuro-oncology. The question for the field is whether intratumoral radiotherapeutics, coupled with functional imaging and cerebrospinal fluid cell enumeration, can deliver sufficiently robust evidence to satisfy regulators and payers in indications long dominated by palliative standards and single-arm datasets.
This matters now because treatment options for rGBM and LM remain constrained, survival is measured in months, and clinicians need tools that meaningfully shift outcomes. For HCPs, the data reinforce a workflow that blends neurosurgical placement, nuclear medicine dosing, and advanced imaging to guide therapy—an approach that demands coordination and training but could personalize care in ways conventional chemotherapies cannot. For payers, the value story hinges on overall survival and quality-of-life gains relative to historical controls like bevacizumab in rGBM, along with evidence that image-derived metrics predict benefit. If imaging biomarkers and CSF-based assays such as CNSide can be validated prospectively, they could become critical in patient selection, response assessment, and utilization management.
The updates also intersect with broader industry dynamics. Radiopharmaceuticals have been a hotbed of M&A and investment, but the action has centered on systemic ligands in prostate and neuroendocrine tumors. CNS applications represent a frontier with distinct operational and reimbursement requirements: short half-life isotopes, secure supply and distribution, specialized imaging, and procedure-based delivery likely concentrated in centers of excellence. Plus’s reliance on non-dilutive funding from NCI, CPRIT, and DoD, and its integration with CNSide Diagnostics, highlight two trends shaping small-cap biotech strategy: capital-efficient development and bundling of therapy with decision-support diagnostics. Both could become differentiators if regulatory policy around laboratory-developed tests tightens and if payers demand biomarker-driven proof of utility.
Commercial teams should plan for a hub-and-spoke activation model, site readiness programs that knit together neurosurgery and nuclear medicine, and early HEOR that links dosimetry, imaging coverage, and survival to justify premium pricing and potential pass-through or new technology add-on payments. Medical Affairs will need to standardize imaging protocols, educate multidisciplinary tumor boards, and stand up pragmatic RWE to close evidence gaps inherent to single-arm studies, particularly in LM where randomized trials are rare.
The next inflection will be whether Phase 2 GBM data and accumulating LM experience can translate imaging and CSF metrics into decision-grade endpoints and payer confidence. If intratumoral dosimetry reliably predicts survival and can be operationalized at scale, neuro-oncology could become the proving ground for a new class of precision radiotherapeutics—and the catalyst for fresh partnering across radiopharma, neurosurgery, and diagnostics.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
